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study to define the spinal cord injury-induced
immune depression syndrome (SCI-IDS) - study
protocol and interim feasibility data
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Abstract
Background: Infections are the leading cause of death in the acute phase following spinal cord injury and qualify
as independent risk factor for poor neurological outcome (“disease modifying factor”). The enhanced susceptibility
for infections is not stringently explained by the increased risk of aspiration in tetraplegic patients, neurogenic
bladder dysfunction, or by high-dose methylprednisolone treatment. Experimental and clinical pilot data suggest
that spinal cord injury disrupts the balanced interplay between the central nervous system and the immune system.
The primary hypothesis is that the Spinal Cord Injury-induced Immune Depression Syndrome (SCI-IDS) is ‘neurogenic’
including deactivation of adaptive and innate immunity with decreased HLA-DR expression on monocytes as a key
surrogate parameter. Secondary hypotheses are that the Immune Depression Syndrome is i) injury level- and ii)
severity-dependent, iii) triggers transient lymphopenia, and iv) causes qualitative functional leukocyte deficits,
which may endure the post-acute phase after spinal cord injury.
Methods/Design: SCIentinel is a prospective, international, multicenter study aiming to recruit about 118 patients
with acute spinal cord injury or control patients with acute vertebral fracture without neurological deficits
scheduled for spinal surgery. The assessment points are: i) <31 hours, ii) 31–55 hours, iii) 7 days, iv) 14 days, and v)
10 weeks post-trauma. Assessment includes infections, concomitant injury, medication and neurological classification
using American Spinal Injury Association impairment scale (AIS) and neurological level. Laboratory analyses
comprise haematological profiling, immunophenotyping, including HLA-DR expression on monocytes, cytokines
and gene expression of immune modulators. We provide an administrative interim analysis of the recruitment
schedule of the trial.
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Discussion: The objectives are to characterize the dysfunction of the innate and adaptive immune system
after spinal cord injury and to explore its proposed ‘neurogenic’ origin by analyzing its correlation with lesion
height and severity. The trial protocol considers difficulties of enrolment in an acute setting, and loss to
follow up. The administrative interim analysis confirmed the feasibility of the protocol. Better understanding
of the SCI-IDS is crucial to reduce co-morbidities and thereby to attenuate the impact of disease modifying
factors to protect neurological “outcome at risk”. This putatively results in improved spinal cord injury
medical care.
Trial registration: DRKS-ID: DRKS00000122 (German Clinical Trials Registry)
Keywords: Spinal cord injury, Immune paralysis, Lesion height dependency, High-dose methylprednisolone
treatment, Infections
Background
The effective treatment of worldwide 2.5 million paralyzed,
spinal cord injured patients represents an unmet medical
need to date [1]. In addition, the numbers of non-traumatic
cases (e.g. tumor, cervical spondylotic myelopathy) of spinal
cord injury (SCI) are increasing. Infections, i.e. pneumonia
and urinary tract infections are a leading cause of morbidity
and mortality in patients with acute SCI [2,3]. However,
attributing infections to motor-paralysis related dysfunction
alone does not sufficiently explain the increased suscep-
tibility to develop infections after SCI. Among others,
dysphagia occurs also in healthy patients over night without
causing pneumonia. Thus, higher rates of dysphagia in SCI
patients with cervical lesions do not solely explain increased
rates of pneumonia.
It has been elucidated recently that SCI might increase
predisposition to infections by Central Nervous System
(CNS)-specific mechanisms: CNS-injury induces a disturb-
ance of the normally well-balanced interaction between
the immune system and the CNS resulting in a Spinal Cord
Injury-induced Immune Depression Syndrome (SCI-IDS)
[4-9]. Presence of SCI-IDS has been verified independently
after experimental [10] and human SCI [11]. In brief, SCI
‘neurogenically’ ablates the immune system and enhances
susceptibility to develop infections, which in turn might
cause a generalized wound healing impairment – also
affecting wound-healing/repair of the spinal cord lesion
itself. Of note, besides increasing the mortality, infections
represent an independent risk factor for impaired functional
neurological recovery e.g. by i) reducing the conversion rate
from being ‘completely’ to ‘incompletely’ paralyzed and ii)
impairing gain of American Spinal Injury Association
(ASIA) motor scores [12].
Based on preclinical and first clinical observations within
a pilot trial [5,6] we aim to develop prognostic surrogate
parameters in order to predict and selectively identify
patients ‘at risk’ to develop infections. Here, we propose to
establish parameters after human SCI, which have been
tested in other clinical paradigms of elevated infectious risk
such as status post cardiopulmonary bypass [13] and after
ischemic CNS injury [14,15]. Therefore, we apply methods
established in humans, such as human leukocyte antigen
(HLA)-DR expression on monocytes [14] and Concanava-
lin A (ConA)-induced cytokine expression in whole blood
samples, as surrogate markers of SCI-IDS. HLA-DR
expression on monocytes serves as primary outcome
measure. Moreover, a peripheral blood leukocyte mRNA
expression profile encoding for immune modulatory
proteins will be investigated to sense and therefore predict
an evolving immune suppression as early as possible.
Furthermore, we will measure the presence of individual
predisposition for infections by assessing polymorphisms in
coding areas of MHC-proteins, toll-like pattern-recognition
receptors and selected cytokines [16].
The prevention of infections facilitated by the ‘neuro-
genic’ immune suppression syndrome (with its pronounced
penetrance referred to as ‘immune paralysis’) aims to (i)
decrease mortality, (ii) reduce expensive hospitalization
time and, (iii) improve the functional outcome, since SCI
patients suffering infections are prone to develop inferior
neurological recovery [12]. Molecular treatment strategies
aiming to foster axonal plasticity and repair might be
complemented by approaches that intend to protect the
intrinsic neurological recovery potential. Given a realistic
therapeutic timeframe of opportunity after SCI, the early
identification of SCI-patients ‘at risk’ would offer a ‘pre-
ventive’ option to treat infections earlier and thereby avoid
their detrimental consequences. This protective strategy
might save neurological function ‘at risk’ and thereby
improve quality of life. In addition, it would be possible
to unmask putative confounding factors that influence
neurological outcome measures of relevance for inter-
ventional or rehabilitative trials [12].
A solid body of evidence demonstrates that SCI is associ-
ated with an early onset of immune suppression (SCI-IDS).
Identification of SCI patients as immune compromised is
a clinically relevant finding, yet widely underappreciated
and warranting further analysis. In order to decipher the
underlying mechanisms of SCI-IDS we are following-up
on experimental results [5,7,10,17], clinical pilot trials
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[6,8], and cohort studies [9,18,19] with the international
SCIentinel trial. We outline the study protocol and design,
define the main outcome parameters, and provide the
results of an administrative interim analysis.
Methods/Design
Study design, study coordination, and participating
centers
The “SCIentinel” trial is designed as a prospective mul-
ticenter study for the detailed evaluation of the SCI-IDS
(Figure 1). The overall coordination is performed by the
Department of Experimental Neurology, Clinical and
Experimental Spinal Cord Injury Research (Neuroparaple-
giology) at the Charité University Hospital, Campus Mitte,
Berlin, Germany.
The study comprises seven recruiting trial centers with
a specialization in SCI treatment: Treatment Center for
Spinal Cord Injuries, Trauma Hospital Berlin, Germany;
Center for Musculoskeletal Surgery (Campus Virchow
Clinic); Department of Trauma and Reconstructive Surgery
(Campus Benjamin Franklin); Department of Neurosurgery
(Campus Virchow Clinic and Campus Benjamin Franklin),
Charité University Hospital Berlin, Germany; Division
of Trauma Surgery, University Hospital Zurich; Spinal
Cord Injury Center, University Hospital Balgrist, Zurich,
Switzerland, and the Department of Neurosurgery, Toronto
Western Hospital, Toronto, Canada. The study investi-
gators are physicians specialized and experienced in the
treatment and rehabilitation of patients with SCI.
Duration
A recruitment period of 30 months is scheduled. Each
patient will be followed-up to three months post-trauma.
After completion of recruitment and follow-up, a further
six months period is planned for the database clearing, the
statistical evaluation and the preparation of the trial report.
Enrolment has started in August 2011. Expected study
completion date is the first quartile of 2014. Publication of
the trial report is scheduled for the end of the year 2014.
Ethics
The protocol received approval by the local Ethics Com-
mittees: Ethical Committee of the Charite – Universitäts-
medizin Berlin (EA1/001/09), University Health Network
Research Ethics Board, Toronto (REB10-0384-AE), Cantonal
Ethics Commission, Zurich (KEK-ZH-Nr. 2011–0059).
Participants will be informed about the trial, orally and
in written form, using patient’s information sheets and
written informed consent will be obtained. This study
complies with the Helsinki Declaration, the principles
of Good Clinical Practice (GCP) and the Personal Data
Protection Act. The study will also be carried out in
keeping with local legal and regulatory requirements.
The study has been registered in the German Clinical
Trials Registry (DRKS-ID: DRKS00000122).
Participants
A number of 118 patients is planned to be allocated to the
study for examination of the primary endpoint. In order to
Figure 1 Multicenter structure and trial management. Legend: Scheme of the trial workflow. BL-C = Berlin-Charité, BL-T = Berlin-Trauma-Hospital;
TU = Biometry Tübingen; ZH-U = Zurich-University Hospital; ZH-B = Zurich-Balgrist; TO = University Hospital Toronto.
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allow for investigation of the role of disturbed innervation
of the major splanchnic nerve (T5-T9) as linked to alter-
ations of the immune system function, we categorize SCI
patients into lesions with the neurological level T4 or
above versus lesions neurological level T5 or below.
Therefore, the patients will be assigned to 3 groups: i)
48 SCI-patients with a neurological level T4 or above; ii)
31 patients with a neurological level T5 or below; iii) 39
patients with an acute vertebral fracture, but without SCI
as control group (Figure 2).
The study will not interfere with methylprednisolone
treatment per site regimens and patients will be also en-
rolled, but are excluded from the analysis of the primary
endpoint. Based on experiences from the clinical practice
in the recruiting trial centers the rate of cases treated with
methylprednisolone is estimated to be 5-10%. Thus, up to
12 patients will additionally be included for explorative
examination of methylprednisolone-related alterations of
the immune system after SCI (Figure 2).
Sample size calculation
The primary endpoint is a difference in HLA-DR ex-
pression on monocytes exactly quantified by analysing
antibody-binding molecules/cell within the first week
(day 3–4) post-trauma. Numbers of patients to be enrolled
were calculated on the basis of a pilot study (n = 26) [6].
The sample size calculation was performed for an effect size
of 0.18. The type one error was be set to 0.05 (two-sided);
type two error was set to 0.2. The number of patients eli-
gible for evaluation (for testing the hypothesis by the one
way anova) is 56 in total (software nquery, version 7.0).
Due to an expected rate of drop-outs/missing data of 50%
and non-parametric testing, where applicable, the number
of patients to be recruited increases to 118 in total.
The expected rate of drop-outs/missing data relates to the
structural conditions of acute SCI care in terms of i)
delayed transfer to specialized SCI trial centers after
primary care in external non-specialized centers and ii) loss
to follow up due to discharge from inpatient rehabilitation,
Figure 2 Relay-interaction of the immune system and the central nervous system. Legend: Groups for primary comparison in relation to the
major sympathetic outflow (vegetative innervation). In Group I (SCI of the neurological level T4 or above) the lesion is localized within the spinal
segments C2-T5, resulting in a disturbance of the sympathetic innervation of immunologically relevant organs through the coeliac ganglion and
further ganglia connected through lower segments of the spinal cord. Of note, the neurological level is defined by the ISNCSCI as the most cranial
segment with normal sensory function and a muscle grade of at least 3/5 with normal function in the segments above on both sides of the body, i.e.
in case of a neurological level T4, the lesion begins in the segment T5. In Group II (SCI of the neurological level T5 or below) the lesion is located in the
spinal segment T6 or below. Thus, the sympathetic outflow to the coeliac ganglion is expected being only partially disrupted or completely preserved.
Group III consists of patients with vertebral fracture alone without injury to the spinal cord (control). Here, the sympathetic innervation is intact.
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particularly in the control group or in cases of mild
incomplete SCI. Consequently, to allow for a completion
of the study within a feasible time period consideration of
missing values is unavoidable.
The sample size calculation was performed taking the
asymmetric natural distribution of the neurological lesion
level into account [20]. Injury to the cervical and high thor-
acic spinal cord has the highest incidence and represents
the largest group of SCI patients. Thus, the relation of the
3 groups to each other was determined as follows based on
the pilot trial data i) 41% (n = 48); ii) 26% (n = 31); iii) 33%
(n = 39).
Enrolment and eligibility criteria
With the seven study centers treating 20 to 60 acute SCI
patients admitted to the emergency ward of each center
per year we estimate to screen about 200 SCI patients per
year and about 40 of them are expected to meet eligibility
criteria (Table 1).
Investigators will evaluate the patients after admission
to the emergency ward for eligibility. Before final inclusion
into the study the investigator will conduct an interview
with the patients to verify the inclusion- and exclusion-
criteria and obtain written informed consent.
Assessment time points
Measurements and observations are scheduled in all groups
in the same manner (Figure 3). An inclusion assessment
will be performed at the study entry and is documented
in a case report form (CRF). The baseline CRF includes
the neurological classification, assessment of injury date
and time, medical history, concomitant injury, acute
SCI therapy concerning high-dose methylprednisolone
treatment as well as surgical intervention.
At the 5 study visits, equal blood samples and clinical
data will be obtained. The clinical data comprise infections,
medication, surgery, and blood transfusions. The first
assessment should be completed as early as feasible after
the injury, preferably before surgery, otherwise at least
within 31 hours post-injury. The second assessment point
refers to a time window of 31–55 hours post-injury. To
ensure a sufficient time interval to the first assessment the
second one should be performed on the following day at
the earliest. This allows a better intra-individual analysis.
The visits 3, 4 and 5 refer to day 7, 14 and to 10 weeks
after injury, respectively. Blood withdrawals, except at time
point 1 should be performed between 7:00 and 11:00 am.
This setting determines the influence of the circadian
rhythm to a minimum.
In the case, if it is unavoidable that a patient may be
assigned to the study later as 31 hours (delayed recruit-
ment) e.g., due to later admission or transfer to a study
center (see also sample size calculation), study inclusion
is tolerated at any later time point. In individual cases of
delayed recruitment or patient’s absence, documentation
of visits 2–5 may be scheduled in extended time windows
(Figure 3).
Definition of infections
The most prevalent infections after SCI, in detail chest
infections and urinary tract infections, are diagnosed and
documented in the study according to established defini-
tions of disease to ensure a biometric comparability
[15,21,22] (Table 2). Additionally, a distinction is made
between non-symptomatic and symptomatic urinary tract
infections, i.e. the latter are classified with regard to evi-
dence of fever, increased spasticity, bladder spasm, supra-
pubic or flank pain, autonomic hyperreflexia, malaise, or
lethargy. All other infections are documented according to
the usual diagnostic criteria of the participating centers.
Neurological classification
The neurological evaluation is performed according to the
International Standards for Neurological Classification
of Spinal Cord Injury (ISNCSCI), a revision of ASIA
classification [23,24]. Within the ISNCSCI-regime the
ASIA impairment scale (AIS) as a measure for complete-
ness of the injury, and the single neurological level of the
lesion are assessed.
Table 1 Eligibility criteria
Inclusion criteria
(1) Patients with acute isolated spinal cord injury (AIS A-D) planned
for surgical stabilization and decompression, lesion may include
more than 1 segment
(2) Patients with acute isolated spinal fracture planned for surgical
stabilization, lesion may include more than 1 segment
(3) ≥ 2 spinal cord or vertebral lesions definable one from another
(4) Legal age of the patient
(5) Documented informed consent of the patient
Exclusion criteria
(1) Non-traumatic spinal cord injury
(2) 2 or more spinal cord or vertebral lesions definable one from
another
(3) Severe polytrauma (definition: patients with severe injuries of
life-sustaining organ systems, which per se and in the acute phase
are life-threatening (e.g., severe pelvic trauma, severe body cavity
injuries)
(4) Concomitant traumatic brain injury (TBI) (definition: i) Patients
with persisting neurological deficit in consequence of the TBI, ii)
patient with severe TBI (Glasgow Coma Scale≤ 8), and iii) patients
with intracranial pressure monitoring sensors.)
(5) Neoplasia and/or antineoplastic therapy
(6) Rheumatic disease, collagenosis, vasculitis or other autoimmune
disease
(7) Preexisting chronic infectious disease (before the injury)
(8) Preexisting systemic steroid treatment
(9) Severe alcohol or drug addiction
(10) Pregnancy, lactation
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Blood sample handling
Peripheral blood is collected under sterile conditions
from each participant at each visit. All samples are labeled
with a six-digit pseudonym and any personal information
of the participants is removed. Overall, one 2 ml and
one 6 ml Ethylenediaminetetraacetic acid (EDTA) BD
Vacutainer®, two 3 ml Heparin BD Vacutainer® and one
8.5 ml Serum BD Vacutainer® are needed. Furthermore
one 5 ml Cyto-Chex® blood collection tube (BCT) and
two 2.5 ml PAXgene™ RNA tubes are collected (Figure 4).
Blood samples for flow cytometric analysis are analyzed as
soon as possible, preferably within 24 hours latest within
48 hours. Preservation of intracellular and extracellular
surface markers is ensured by using Cyto-Chex® BCT
[25,26].
Supernatants from whole blood stimulation and further
blood samples for secondary outcome measures are stored
at −80°C for subsequent batch analysis (Figure 4). In the
trial centers at Berlin and Zurich, one additional 8 ml
BD Vacutainer® CPT™/Ficoll™ tube is collected for im-
mediate preparation of Peripheral Blood Mononuclear
Cells (PBMCs) for storage in liquid nitrogen. The handling
of samples follows identical standard operating procedures
and checklists at all trial centers.
Immune profiling of SCI-IDS
The following investigations are performed to determine
the immune status: i) immunophenotyping with lympho-
cyte subpopulations (B, T, NK cells), T cell subpopulation
(CD3, CD4, CD8) and monocytic HLA-DR expression; ii)
ex vivo T lymphocyte cytokine secretion such as ConA-
induced IFN-g, TNF-α, IL-2, IL-4, IL-5, IL-10 secretion
and staphylococcal enterotoxin B (SEB)-induced IL-17
production; iii) gene expression analysis for immune
Figure 3 Longitudinal trial design. Legend: Assessment points and time frames. The starting point of the time line is the time of injury not the
time of surgery. In the case of difficulties in scheduling the visits 2 to 5 may be conducted within the indicated time windows (italic). The
circadian rhythmics are respected.
Table 2 Diagnostic criteria for chest infection and urinary tract infection
Type of infection Criteria
Chest infection, if ≥ 3 criteria apply Temperature < 36.0°C or ≥ 37.5°C
Putrid secretion
Pathological respiration (rales, bronchial breathing, tachypnea > 22/min)
Opacities in chest x ray (required for the diagnosis of pneumonia)
Detection of pathogenic germs in sputum
pO2 < 70 mmHg/O2 saturation < 93%
Urinary tract infection, if ≥ 1 criteria apply Bacteriuria with bacterial count > 105 cells/ml
Leukocyturia ≥ 100 WBC/mm3, respectively 100.000 WBC/ml
Symptomatic urinary tract infection, if ≥ 1 criteria apply ≥ 1 criteria for urinary tract infection
≥ 1 of the following criteria: fever, suprapubic or flank discomfort, bladder
spasm, increased spasticity, worsening dysreflexia
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activation/deactivation related genes (mRNA expression);
iv) circulating immune modulators: such as IL-6, epineph-
rine; v) indirect infection parameters: procalcitonin,
C-reactive protein (CRP), LBP (lipopolysaccharide-bind-
ing protein).
Immunophenotyping using fluorescence-activated cell
sorting (FACS) including quantitative measurement of
monocytic HLA-DR expression as the primary outcome
measure will be conducted according to standardized
operation procedures established at the Institute of Med-
ical Immunology (Charité - Universitätsmedizin Berlin,
Germany) for clinical diagnostics of an immune suppres-
sion state [14]. HLA-DR belongs to the MHC class II
molecules that are responsible for antigen presentation to
CD4+ T-cells. Monocytic HLA-DR expression reflects the
state of the adoptive immune competence as it is positively
regulated by Th1 cytokines and negatively regulated by
anti-inflammatory cytokines, stress hormones and some
exogenous agents. Furthermore, monocytic HLA-DR
expression is associated with the ability to produce pro-
inflammatory mediators upon challenge by bacterial prod-
ucts such as lipopolysaccharides (LPS). Reduced monocytic
HLA-DR expression has been established to correlate
with an increased risk for infections in critically ill patients
previously [14,27,28].
Quantitative measures of HLA-DR expression
In contrast to the pilot study that measured HLA-DR
expression on different cell types [6], the SCIentinel
study measures quantitatively the amount of HLA-DR
molecules per monocyte (in estimated numbers per cell).
The reliability of the method has been previously approved
in an inter-laboratory study [14].
The principle of the test is as follows. A mixture of
Phycoerythrin (PE) beads conjugated with defined amounts
of PE molecules is measured at the same instrument
settings as the cells incubated with a mix consisting of
anti-human HLA-DR-PE, anti-human CD14-PerCP-Cy5.5,
and an inhibitor of HLA-DR turnover (BD Quantibrite™
HLA-DR/Monocyte reagent, BD Biosciences). The PE
beads facilitate conversion of the FL2 axis into PE mole-
cules bound per cell. The known ratio of PE to anti-HLA-
DR antibody is used to convert the PE molecules per cell
into antibodies per cell (AB/c). The anti-HLA-DR anti-
body, clone L243, reacts with a non-polymorphic HLA-DR
epitope and is conjugated with PE molecules in a ratio of
1:1. The anti-CD14 antibody, clone MοP9, is conjugated
with PerCP-Cy5.5. CD14 is expressed by the majority of
monocytes. In addition, since the cyan dye component of
PerCP-Cy5.5 binds to CD64, the anti-CD14 PerCP-Cy5.5
antibody detects all monocytes (CD14 brightly positive and
weakly positive). The immunodiagnostical thresholds de-
lineating a graded SCI-IDS penetrance are defined as indi-
cated in Table 3 and were developed based on previous
clinical trials after CNS injury [27].
Data management
Data are collected on a paper CRF (pCRF) basis. All
patient’s data are managed with a six-digit pseudonym.
At the coordinating center personnel familiar with the trial
protocol check the filled pCRFs for completeness and
consistency. Implausible or missing data may be corrected
Figure 4 SCI-IDS Immunephenotyping – qualitative and quantitative measures. Legend: Scheme of blood collection, sample preparation
and analysis procedures. ConA = Concanavalin A, ELISA = Enzyme Linked Immunosorbent Assay, ELISPOT = Enzyme Linked Immunosorbent Spot,
FACS = Fluorescence-activated cell sorting, IFN-g = Interferon-gamma, TNF-g = Tumor necrosis factor – gamma.
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or added after consulting the investigator at the trial site
through the study management (Queries). The corrected
documents will be archived together with the completed
CRFs. Data are entered and stored electronically in a
database (Access) and are independently double-checked
for correctness. The database has secured and restricted
access centralized at IT-Center of Charité-Universitätsme-
dizin Berlin, Germany. Data backups are performed on a
daily basis.
Interim evaluation of recruitment status
An administrative interim evaluation for control of the
estimated recruitment schedule after enrolment and follow
up of approximately 50% of the calculated sample size has
been performed. Patients recruited until April 2013 and
followed up to July 2013 were included. The groups for
comparison were analyzed for their concordance with
the estimated sample size (Table 4). Furthermore the
completeness of data for the main laboratory outcome
parameters (flow cytometry) at each time point was
assessed within the ‘per protocol’ population (Table 5).
Statistical analysis
Data analysis of the primary endpoint consists of a com-
parison, between the 3 groups at the early and subsequent
follow-up assessment points using one-way ANOVA or
nonparametric tests, if appropriate. The analysis will be
performed using the full dataset comprising all patients
included according to the criteria as defined in the study
protocol. In addition, in patients with complete intra-
individual datasets also changes over time within the
groups will be assessed with descriptive methods. Further-
more, in the case of a relevant amount of missing values,
multiple imputation will be taken into consideration
for verification of the analysis of the original data. Data
obtained from patients treated with methylprednisolone
will be primarily analyzed in a casuistic manner.
The statistical analysis of the administrative interim
evaluation has been performed using SPSS for Macintosh,
Version 19.0.
Discussion
The SCIentinel trial aims to define SCI-IDS characteristics.
We investigate the hypothesis that SCI-IDS is not restricted
to quantitative immune suppression (cell depletion) [5-8],
but also affects qualitative immune function of ‘spared’
immune cells. Qualitative dysfunction of immune cells
translates into suppressed innate and adaptive immune
cell function that finally leads to impaired host defense
[29]. Qualitative effects may extend into chronic SCI [29]
and therefore the identification of patients prone to develop
infections is also relevant during long-term follow up.
Moreover, according to the proposed ‘neurogenic’ origin
of the SCI-IDS we suggest rostral and complete spinal
cord lesions to be associated with a more severe immune
depression syndrome compared to more caudal or incom-
plete lesions. Furthermore we intend to investigate a puta-
tive sustained extension into chronic disease phases
after SCI. Together, this is embedded the longitudinal
prospective trial design and in a power calculation that
takes differences between rostral and caudal neurological
levels into account. In addition, the impact of facultative
co-treatment with high dose methylprednisolone, which
may further aggravate SCI-IDS is accessible for descriptive
analysis.
Spine trauma
In order to differentiate the SCI-related ‘neurogenic’ effect
on the immune system from the ‘non-neurogenic’ effect
of the surgical intervention/trauma itself (activation of the
stress axis/post-aggression syndrome) the study protocol
incorporates a control group of patients with isolated
vertebral fracture without neurological deficit. Of note,
this refinement of the control group definition by the
SCIentinel trial overcomes a weakness of the pilot study
where patients after smaller surgical interventions such
as arthroscopy served as control group [6], which only
insufficiently mimics the post-aggression syndrome caused
by surgical stabilization of the spine.
Table 3 Thresholds for the interpretation of the analysis
of HLA-DR expression on monocytes
Antibodies/cell Interpretation
> 15 000 Normal diagnostic findings
10 000 – 15 000 Immunodepression
5 000–10 000 Borderline immunoparalysis
< 5 000 Immunoparalysis
Table 4 Administrative interim analysis of the recruitment status for patients without high-dose methylprednisolone
treatment
Groups Overall n (%) SCI T4 and above n (%) SCI T5 and below n (%) Control group n (%) Drop out n
Estimated sample size 118 (100) 48 (100) 31 (100) 39 (100) n.a.
Enrolled partients 60 (51) 28 (58) 11 (35) 17 (44) 4
Legend: Sixty patients without high-dose methylprednisolone treatment were included into the SCIentinel trial from August 2011 to April 2013. The number of
patients recruited into the group of SCI patients of the neurological level T5 or below was slightly smaller than expected. This does not match the natural distribu-
tion of the lesion level and seems to be random. In total, four patients (7%) dropped out of the interim analysis due to occurrence of exclusion criteria.
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In order to evaluate the impact of the lesion height we
assess differences between rostral and caudal spinal cord
lesions. Consequently, SCI patients were divided into two
groups with/without expected impairment of the major
sympathetic outflow and compared with the controls
applying a three-group strategy for analysis (Figure 1).
To assess the effect of lesion severity, we compare
complete (AIS A) with incomplete lesions (AIS B-D) in
a descriptive sub-group analysis.
Eligibility criteria
We defined the eligibility criteria (Table 1) in order to
minimize inclusion bias and to obtain ‘representative’
data. The definitions stipulated in the SCIentinel protocol
are consistent with previously published studies [6,8,18,30].
It was necessary to exclude patients with severe, life
threatening polytrauma or severe TBI in order to limit
variability caused by concomitant injury. For detection
of immune system functionality, it is furthermore essential
to exclude all circumstances combined with pre-existing
alterations in the immunological profile such as chronic
autoimmune diseases and pre-existing systemic treatment
with corticosteroids.
The administrative interim analysis of the SCIentinel
trial has confirmed the feasibility of the eligibility criteria.
From August 2011 to April 2013 n = 64 patients have been
enrolled for the study which represent 37 patients per
year. Thus, the enrolment status is within the expected
range. Four of the 64 patients (6%) were treated with
high-dose methylprednisolone. Therefore, those patients
are to be excluded from the ‘per protocol’ analysis. How-
ever, casuistic studies on immunosuppressive effects of
methylprednisolone treatment in the context of the SCI-
IDS are enabled. The remaining 60 patients represent 51%
of the estimated sample size (Table 4).
Observation period
Observational time points (Figure 2) range from acute to
sub-acute stages after SCI comparable to the pilot study
[6]. Here, the time schedule corresponded to the hallmarks
of parenchymal inflammation following SCI. The imple-
mentation of sub-acute assessments is in line with previous
trials that demonstrated mid- and long-term alterations of
the immune system after SCI [8,18,19].
The setting of defined time corridors instead of time
points provides a more complete tracking of the partici-
pants. In order to prevent a high amount of missing
datasets due to loss to follow-up, the protocol allows an
inclusion at each documentation time point.
The administrative interim analysis of data completeness
for the main laboratory parameters indicates - depending
on the group or visit – a completeness of data between
24% and 91% with critical rates of completeness at visit 1
and visit 5, particularly in the control group (Table 5). As a
consequence, the recruiting centers have been requested
to enroll the patients as soon as possible after injury.
Additionally, we intend to address the challenge of loss
to follow up by travelling to external rehabilitation
centers or by phone calls to remind patients of their
study visit at the outpatient clinic. The rate of complete
longitudinal datasets ranges between 18% and 36% but
is expected to increase during the further trial course
since trial routines are better established. Noteworthy,
the sample size calculation takes 50% of missing values
into account and was performed for one-way ANOVA.
Repeated measure analysis requires lower sample sizes.
Therefore, it seems feasible that a relevant amount of
complete longitudinal datasets can be achieved also for
the description of the intra-individual course of the SCI-
IDS. Pursuing this study concept, serial investigations on
short- and mid-term changes of the immunological func-
tion are provided.
Table 5 Administrative interim analysis of the completeness of laboratory data (flow cytometry) for each visit relative
to the number of enrolled patients feasible for ‘per protocol’ analysis
Groups Visit 1 Visit 2 Visit 3 Visit 4 Visit 5
Overall n = 56 Complete data n 32 38 44 44 25
(% of ‘per protocol’ population) (57) (68) (79) (79) (45)
SCI T4 and above n = 28 Complete data n 17 20 22 22 16
(% of ‘per protocol’ population) (61) (71) (79) (79) (57)
SCI T5 and below n = 11 Complete data n 6 6 8 10 5
(% of ‘per protocol’ population) (55) (55) (73) (91) (45)
Control group n = 17 Complete data n 9 12 14 12 4
(% of ‘per protocol’ population) (53) (71) (82) (71) (24)
Legend: The completeness of the main laboratory data was calculated for the three groups relative to the number of enrolled patients feasible for ‘per protocol’
analysis. The sample size calculation takes a 50% rate of drop out or missing values into account. Considering the drop out rate < 10% at the current stage of the
trial, a 60% rate of data completeness is acceptable. Critical rates of overall completeness are observed at visit 1 and visit 5 and relate mainly to the control group
and to patients with neurological level T5 or below.
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Clinical observations
For the clinical research, it is imperative to use reliable
reproducible clinical tests. The ISNCSCI standards revised
over the years to provide better, more specific definitions
[23,24]. We incorporated the AIS and the single neuro-
logical level into the trial protocol for neurological baseline
characterization of SCI patients.
The determination of infections is of crucial importance
in this study. Prevailing infectious complications of SCI
patients are pulmonary and urinary tract infections [4].
Cameron and colleagues recently provided a review consist-
ing of 12 articles of urinary tract infection (UTI) screening
for SCI [31]. Noteworthy, there is no universal definition
of UTI used in the literature allowing substantial hetero-
geneity. The American Paraplegia Society (APS) recom-
mends to base the diagnosis of UTI solely on bacteriuria,
with a threshold of 102 colony-forming units (cfu)/mL for
SCI patients [32]. However, up to 75% of samples taken
from asymptomatic SCI male patients under intermittent
catheterization contain ≥ 102 cfu/mL [32]. Thus, a threshold
of 102 cfu/mL is associated with low specificity, leading to
an excess of treatment, with the risk of the emergence of
resistant bacteria, adverse events, and unnecessary expense.
In consequence, we defined according to the National
group on urologic rehabilitation of paraplegics urinary tract
infection as bacteriuria greater than 105 cells/ml or WBC
count of more than 100/mm3 [21].
Regarding the development of chest infection criteria
defined by Mann et al. were incorporated [22]. For the
diagnosis of pneumonia the finding of infiltrates or opacity
in chest X-ray will be required consistent with Haeusler
et al. who used similar criteria in the analysis of cellular
immunodepression preceding infectious complications after
acute ischemic stroke [15].
In summary, the clinical assessments and definitions
used in the SCIentinel study allow for collection of reliable
and reproducible data.
Primary outcome measure
For meeting the purpose of a more comprehensive
characterization of the SCI-IDS and establishing prog-
nostic surrogate parameters, it is essential to implement
specific parameters, readily validated in clinical immun-
ology, robust and reproducible [14]. Quantification of
immune cell populations in the blood using FACS is a
clinically established and precise method that qualifies as
primary outcome measure. Our primary measure is the
determination of HLA-DR-molecules per monocyte.
Alterations in HLA-DR expression on monocytes occur
early enough to identify patients at high risk for relevant
immune depression and consecutive development of
infections. Significantly decreased monocytic HLA-DR
levels have been observed as early as day one after acute
cerebral ischemia in patients who developed infectious
complications in comparison to patients with an uncom-
plicated clinical course [27]. Furthermore, the method is
already established and available in centralized immuno-
logical laboratories. It has sufficient diagnostic specificity
as a basis for clinical decision-making and therefore is
clinically highly relevant. Moreover, we implemented a
large setting of secondary endpoints for the development
of very early predictive parameters, for example on the
level of mRNA expression.
Possible consequences
The objective of this study is the longitudinal character-
ization of immunological markers of the innate and ac-
quired immune system after traumatic SCI. Furthermore,
the aim is to detect diagnostic surrogate parameters for
the clinical application after SCI. The characterization of a
causative relationship between the lesion level and/or SCI
severity and the type and/or extent of the immune response
after SCI - including a critical characterization of the meth-
ylprednisolone effect - is essential for the implementation
of therapeutic studies. Understanding and recognition
of the immunological dysfunction and the altered sus-
ceptibility to infections may then assist in consecutive
decision-making. This is relevant for the stratification of
patients who are at high or low risk for infectious compli-
cations [33]. In addition, these findings may also hold the
key for early therapeutic immunomodulation aiming to
improve overall survival by anticipation and prevention of
life-threatening infectious complications.
Abbreviations
ASIA: American Spinal Injury Association; AIS: ASIA impairment scale;
BCT: Blood collection tube; CON A: Concanavalin A; CRF: Case report form;
CRP: C-reactive protein; FACS: Fluorescence-activated cell sorting;
EDTA: Ethylenediaminetetraacetic acid; GCP: Good clinical practice;
HLA: Human leukocyte antigen; ISNCSCI: International standards for
neurological classification of spinal cord injury; LPS: Lipopolysaccharides;
PBMC: Peripheral blood mononuclear cell; PE: Phycoerythrin; SCI: Spinal cord
injury; SCI-IDS: Spinal cord injury – induced immune depression syndrome;
SEB: Staphylococcal enterotoxin B; TBI: Traumatic brain injury; UTI: Urinary
tract infection.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MAK, CD, CM, JMS designed the trial protocol and wrote the first draft of the
manuscript. TL, PC, AN, GAW, AC, GL, NN, MGF, PM, HDV, UD reviewed the
trial protocol. All authors critically revised the manuscript draft for important
intellectual content. MAK, CM, PC, HDV, BB, HP, VF, JMS contributed to the
establishment of analytical methods. MAK, CD, TL, EP, RW, PC, AN, KDS, GAW,
AC, GL, NN, MGF, PV, MC, JD, WE, AE, NU, UK, RH, RROS, IL, VF JMS
substantially contributed to the sample and data acquisition. MAK, CD, HP,
VF, JMS were responsible for overall trial coordination and supervision. MAK,
CD, RW, PC, GL, NN, MC, BB, RCH, RROS, IL, VF were responsible for local trial
management. CM, PC, MGF, PM, HDV, UD provided technical support. MAK,
RW were responsible for data management. MK performed the interim
feasibility analysis. JMS obtained funding. All authors have read and
approved the final version of the manuscript.
Kopp et al. BMC Neurology 2013, 13:168 Page 10 of 12
http://www.biomedcentral.com/1471-2377/13/168
Acknowledgements
We are thankful to all patients who gave their consent to participate in the
trial during a critical period of their life. Furthermore, we would like to thank
Susann Klingbeil for her contribution to the trial protocol development and
Ricarda Locher, Daniel Peukert, and Vincent Prinz for their support in sample
acquisition. We acknowledge Johanna Schöner for her contribution to the
data management. The project has received funding from the German Research
Council (DFG; Cluster of Excellence NeuroCure), the Berlin-Brandenburg Center
for Regenerative Therapies (BCRT Grant number 81717034) and the Wings for Life
Spinal Cord Research Foundation (Grant Number WfL-DE-006/1). RCH receives
funding from the Elsa-Neumann-Scholarship program (Grant Number H57021).
RW is an awarded scholar of the ‘Studienstiftung des deutschen Volkes’
(Grant Number 186392).
Author details
1Department of Neurology and Experimental Neurology, Charité -
Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany. 2Clinical and
Experimental Spinal Cord Injury Research (Neuroparaplegiology), Charité -
Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany.
3Department of Musculoskeletal Surgery, Charité - Universitätsmedizin Berlin,
Augustenburger Platz 1, 13353 Berlin, Germany. 4Institute of Medical
Immunology, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1,
13353 Berlin, Germany. 5Berlin-Brandenburg Center for Regenerative
Therapies (BCRT), Charité - Universitätsmedizin Berlin, Augustenburger Platz
1, 13353 Berlin, Germany. 6Department of Immunology, Labor Berlin –
Charité Vivantes GmbH, Sylter Straße 2, 13353 Berlin, Germany. 7Treatment
Centre for Spinal Cord Injuries, Trauma Hospital Berlin, Warener Straße 7,
12683 Berlin, Germany. 8Division of Trauma Surgery, University Hospital of
Zürich, Sternwartstrasse 14, 8091 Zurich, Switzerland. 9Spinal Cord Injury
Center, University Hospital Balgrist, Forchstrasse 340, 8008 Zurich,
Switzerland. 10Department of Neurosurgery, University of Toronto, 399
Bathurst St, Toronto, ON M5T 2S8 Canada. 11Department of Neurosurgery,
Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin,
Germany. 12Centre for Trauma- and Reconstructive Surgery, Charité - Univer-
sitätsmedizin Berlin, Hindenburgdamm 30, 12200 Berlin, Germany. 13Trauma
Surgery and Orthopedics Clinic, Trauma Hospital Berlin, Warener Straße 7,
12683 Berlin, Germany. 14Department of Clinical Epidemiology and Applied
Biostatistics, Eberhard Karls Universität Tübingen, Silcherstraße 5, 72076
Tübingen, Germany. 15German Center for Neurodegenerative Diseases
(DZNE), c/o Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin,
Germany. 16Center for Stroke Research Berlin, Charité - Universitätsmedizin
Berlin, Charitéplatz 1, 10117 Berlin, Germany.
Received: 24 September 2013 Accepted: 31 October 2013
Published: 9 November 2013
References
1. Thuret S, Moon LD, Gage FH: Therapeutic interventions after spinal cord
injury. Nat Rev Neurosci 2006, 7(8):628–643.
2. DeVivo MJ, Kartus PL, Stover SL, Rutt RD, Fine PR: Cause of death for
patients with spinal cord injuries. Arch Intern Med 1989, 149(8):1761–1766.
3. Soden RJ, Walsh J, Middleton JW, Craven ML, Rutkowski SB, Yeo JD: Causes
of death after spinal cord injury. Spinal Cord 2000, 38(10):604–610.
4. Meisel C, Schwab JM, Prass K, Meisel A, Dirnagl U: Central nervous system injury-
induced immune deficiency syndrome. Nat Rev Neurosci 2005, 6(10):775–786.
5. Riegger T, Conrad S, Liu K, Schluesener HJ, Adibzahdeh M, Schwab JM:
Spinal cord injury-induced immune depression syndrome (SCI-IDS). Eur J
Neurosci 2007, 25(6):1743–1747.
6. Riegger T, Conrad S, Schluesener HJ, Kaps HP, Badke A, Baron C, Gerstein J,
Dietz K, Abdizahdeh M, Schwab JM: Immune depression syndrome
following human spinal cord injury (SCI): a pilot study. Neuroscience 2009,
158(3):1194–1199.
7. Riegger T, Schluesener HJ, Kaps HP, Badke A, Baron C, Gerstein J, Dietz K,
Abdizahdeh M, Schwab JM: Hematologic cellular inflammatory response
following human spinal cord injury. Acta Neuropathol 2003, 106:392.
8. Campagnolo DI, Keller SE, DeLisa JA, Glick TJ, Sipski ML, Schleifer SJ:
Alteration of immune system function in tetraplegics. A pilot study.
Am J Phys Med Rehabil 1994, 73(6):387–393.
9. Cruse JM, Lewis RE Jr, Bishop GR, Kliesch WF, Gaitan E, Britt R: Decreased
immune reactivity and neuroendocrine alterations related to chronic
stress in spinal cord injury and stroke patients. Pathobiology 1993,
61(3–4):183–192.
10. Lucin KM, Sanders VM, Jones TB, Malarkey WB, Popovich PG: Impaired
antibody synthesis after spinal cord injury is level dependent and is due to
sympathetic nervous system dysregulation. Exp Neuro 2007, 207(1):75–84.
11. Furlan JC, Krassioukov AV, Fehlings MG: Hematologic abnormalities within
the first week after acute isolated traumatic cervical spinal cord injury: a
case–control cohort study. Spine (Phila Pa 1976) 2006, 31(23):2674–2683.
12. Failli V, Kopp MA, Gericke C, Martus P, Klingbeil S, Brommer B, Laginha I,
Chen Y, DeVivo MJ, Dirnagl U, et al: Functional neurological recovery after
spinal cord injury is impaired in patients with infections. Brain 2012,
135(Pt 11):3238–3250.
13. Strohmeyer JC, Blume C, Meisel C, Doecke WD, Hummel M, Hoeflich C,
Thiele K, Unbehaun A, Hetzer R, Volk HD: Standardized immune
monitoring for the prediction of infections after cardiopulmonary bypass
surgery in risk patients. Cytometry B Clin Cytom 2003, 53(1):54–62.
14. Docke WD, Hoflich C, Davis KA, Rottgers K, Meisel C, Kiefer P, Weber SU,
Hedwig-Geissing M, Kreuzfelder E, Tschentscher P, et al: Monitoring
temporary immunodepression by flow cytometric measurement of
monocytic HLA-DR expression: a multicenter standardized study.
Clin Chem 2005, 51(12):2341–2347.
15. Haeusler KG, Schmidt WU, Fohring F, Meisel C, Helms T, Jungehulsing GJ,
Nolte CH, Schmolke K, Wegner B, Meisel A, et al: Cellular
immunodepression preceding infectious complications after acute
ischemic stroke in humans. Cerebrovasc Dis 2008, 25(1–2):50–58.
16. Meisel C, Hoflich C, Volk HD: Immune monitoring in SIRS and sepsis based
on the PIRO model. Dtsch Med Wochenschr 2008, 133(45):2332–2336.
17. Held KS, Steward O, Blanc C, Lane TE: Impaired immune responses
following spinal cord injury lead to reduced ability to control viral
infection. Exp Neuro 2010, 226(1):242–253.
18. Campagnolo DI, Dixon D, Schwartz J, Bartlett JA, Keller SE: Altered innate
immunity following spinal cord injury. Spinal Cord 2008, 46(7):477–481.
19. Kliesch WF, Cruse JM, Lewis RE, Bishop GR, Brackin B, Lampton JA:
Restoration of depressed immune function in spinal cord injury patients
receiving rehabilitation therapy. Paraplegia 1996, 34(2):82–90.
20. Marino RJ, Ditunno JF Jr, Donovan WH, Maynard F Jr: Neurologic recovery
after traumatic spinal cord injury: data from the model spinal cord injury
systems. Arch Phys Med Rehabil 1999, 80(11):1391–1396.
21. Burgdörfer H, Heidler H, Madersbacher H, Kutzenberger J, Palmtag H,
Pannek J, Sauerwein D, Stöhrer M, Arbeitskreis Urologische Rehabilitation
Querschnittgelähmter, vol. 4: Manual Neuro-Urologie und Querschnittläh-
mung. Leitlinien zur urologischen Betreuung Querschnittgelähmter.
In Überarbeitete Auflage, 4, Überarbeitete Auflage; 2007.
22. Mann G, Hankey GJ, Cameron D: Swallowing function after stroke:
prognosis and prognostic factors at 6 months. Stroke 1999, 30(4):744–748.
23. Marino RJ, Barros T, Biering-Sorensen F, Burns SP, Donovan WH, Graves DE,
Haak M, Hudson LM, Priebe MM: International standards for neurological
classification of spinal cord injury. J Spinal Cord Med 2003,
26(Suppl 1):S50–S56.
24. Kirshblum SC, Waring W, Biering-Sorensen F, Burns SP, Johansen M,
Schmidt-Read M, Donovan W, Graves D, Jha A, Jones L, et al: Reference for
the 2011 revision of the international standards for neurological classifi-
cation of spinal cord injury. J Spinal Cord Med 2011, 34(6):547–554.
25. Davis C, Wu X, Li W, Fan H, Reddy M: Stability of immunophenotypic
markers in fixed peripheral blood for extended analysis using flow
cytometry. J Immunol Methods 2011, 363(2):158–165.
26. Ng AA, Lee BT, Teo TS, Poidinger M, Connolly JE: Optimal cellular
preservation for high dimensional flow cytometric analysis of
multicentre trials. J Immunol Methods 2012, 385(1–2):79–89.
27. Harms H, Prass K, Meisel C, Klehmet J, Rogge W, Drenckhahn C, Gohler J,
Bereswill S, Gobel U, Wernecke KD, et al: Preventive antibacterial therapy
in acute ischemic stroke: a randomized controlled trial. PLoS One 2008,
3(5):e2158.
28. Landelle C, Lepape A, Voirin N, Tognet E, Venet F, Bohe J, Vanhems P,
Monneret G: Low monocyte human leukocyte antigen-DR is independ-
ently associated with nosocomial infections after septic shock. Intensive
Care Med 2010, 36(11):1859–1866.
29. Zhang Y, Guan Z, Reader B, Shawler T, Mandrekar-Colucci S, Huang K,
Weil Z, Bratasz A, Well J, Powell ND, et al: Autonomic dysreflexia causes
chronic immune suppression after spinal cord injury. J Neurosci 2013,
33(32):12970–12981.
Kopp et al. BMC Neurology 2013, 13:168 Page 11 of 12
http://www.biomedcentral.com/1471-2377/13/168
30. Bao F, Bailey CS, Gurr KR, Bailey SI, Rosas-Arellano MP, Brown A, Dekaban GA,
Weaver LC: Human spinal cord injury causes specific increases in surface ex-
pression of beta integrins on leukocytes. J Neurotrauma 2011, 28(2):269–280.
31. Cameron AP, Rodriguez GM, Schomer KG: Systematic review of urological
followup after spinal cord injury. J Urol 2012, 187(2):391–397.
32. Ronco E, Denys P, Bernede-Bauduin C, Laffont I, Martel P, Salomon J, Bussel
B, Guillemot D, Gaillard JL: Diagnostic criteria of urinary tract infection in
male patients with spinal cord injury. Neurorehabil Neural Repair 2011,
25(4):351–358.
33. Zorner B, Blanckenhorn WU, Dietz V, Group E-SS, Curt A: Clinical algorithm
for improved prediction of ambulation and patient stratification after
incomplete spinal cord injury. J Neurotrauma 2010, 27(1):241–252.
doi:10.1186/1471-2377-13-168
Cite this article as: Kopp et al.: The SCIentinel study - prospective multi-
center study to define the spinal cord injury-induced
immune depression syndrome (SCI-IDS) - study protocol and interim
feasibility data. BMC Neurology 2013 13:168.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Kopp et al. BMC Neurology 2013, 13:168 Page 12 of 12
http://www.biomedcentral.com/1471-2377/13/168
